Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis2018-01-17T17:04:46-05:00
Characterizing Iron Deposition in Multiple Sclerosis Lesions Using Susceptibility Weighted Imaging Characterizing Iron Deposition in Multiple Sclerosis Lesions Using Susceptibility Weighted Imaging2018-01-17T17:01:24-05:00
